Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Genmab A/S

Genmab A/S (GMAB) Stock Overview

Explore Genmab A/S’s financial performance, market position, analyst ratings, and future outlook.

GMAB●NASDAQ
HealthcareBiotechnology
$33.45
$0.04(0.12%)
U.S. Market opens in 59h 50m

Genmab A/S (GMAB)

Meyka AI Score

Z

Key Financials

Market Cap20.5B
P/E Ratio26.11
EPS (TTM)$1.33
ROE0.14%
Fundamental Analysis

AI Price Forecasts

1 Month$34.26
3 Months$31.72
1 Year Target$33.64

GMAB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Genmab A/S (NASDAQ: GMAB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Genmab A/S's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GMAB on the NASDAQ shows an RSI of 73.46, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $33.64 for the NASDAQ listing.

Key metrics behind Genmab A/S's NASDAQ-traded stock include a P/E ratio of 26.11 and a market capitalization of 20.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of GMAB on the NASDAQ.

Price Performance (NASDAQ: GMAB)

1-Day Change
0.12%
5-Day Change
6.83%
1-Month Change
17.91%
3-Month Change
23.66%
6-Month Change
14.20%
Year-to-Date (YTD) Change
8.60%
1-Year Change
36.98%
3-Year Change
-8.73%
5-Year Change
-31.14%
All-Time (Max) Change
787.27%

Contact Information

https://www.genmab.com
45 70 20 27 28
Carl Jacobsens Vej 30, Copenhagen, CD, 2500

Company Facts

30,880 Employees
IPO DateJun 1, 2009
CountryDK
Actively Trading

Frequently Asked Questions